| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/400 | Human,Mouse,Rat |
| ICC | 1/25-1/50 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BIS;BRM;SNF2;SWI2;hBRM;NCBRS;Sth1p;BAF190;SNF2L2;SNF2LA;hSNF2a |
| Entrez GeneID | 6595 |
| clone | 3A7B4 |
| WB Predicted band size | 181.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SMARCA2抗体的参考文献示例(注：文献为示例性概括，实际引用需核实具体来源)：
1. **标题**：*"SMARCA2 regulates a transcriptional program in lung cancer through SWI/SNF complex targeting"*
**作者**：D. Wang et al.
**摘要**：研究利用SMARCA2特异性抗体，通过染色质免疫沉淀(ChIP)和Western blot技术，揭示了SMARCA2在肺癌中调控SWI/SNF复合物依赖性基因表达的机制，并发现其缺失与化疗耐药相关。
2. **标题**：*"A monoclonal antibody against SMARCA2 for functional characterization of chromatin remodeling in AML"*
**作者**：J. Martinez et al.
**摘要**：报道了一种高特异性SMARCA2单克隆抗体的开发，验证了其在流式细胞术和免疫荧光中的应用，证明SMARCA2在急性髓系白血病(AML)中的异常表达与染色质重塑失调相关。
3. **标题**：*"SMARCA2 loss synergizes with EZH2 inhibition in SMARCA4-deficient tumors"*
**作者**：R. Brown et al.
**摘要**：通过免疫组化(IHC)结合SMARCA2抗体，分析肿瘤组织中SMARCA2蛋白水平，发现其缺失可增强EZH2抑制剂在SMARCA4突变癌症中的疗效，提出合成致死治疗策略。
4. **标题**：*"Epigenetic profiling of SMARCA2 in hepatocellular carcinoma using a novel antibody panel"*
**作者**：L. Chen et al.
**摘要**：开发了针对SMARCA2不同表位的抗体组合，用于肝癌组织芯片分析，揭示SMARCA2低表达与患者预后不良及转移风险升高的相关性。
(提示：以上内容为示例，实际文献需通过学术数据库检索确认。)
The SMARCA2 antibody is a key reagent used to detect the SMARCA2 protein (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2), a critical component of the SWI/SNF chromatin remodeling complex. This ATP-dependent complex regulates gene expression by modifying chromatin structure to control DNA accessibility. SMARCA2. also known as BRM (Brahma homolog), shares homology with SMARCA4 (BRG1) and plays roles in cellular processes such as differentiation, proliferation, and DNA repair.
SMARCA2 antibodies are widely employed in research to study protein expression, localization, and function in various tissues and diseases. They are utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Studies using these antibodies have revealed SMARCA2's involvement in cancer, where its loss or mutation is observed in certain malignancies (e.g., lung adenocarcinoma, hematologic cancers), suggesting tumor-suppressive properties. Additionally, SMARCA2 dysregulation has been linked to neurodevelopmental disorders and senescence.
The development and validation of SMARCA2 antibodies require careful specificity testing due to potential cross-reactivity with homologous proteins like SMARCA4. Researchers prioritize antibodies validated in knockout models or orthogonal assays to ensure reliability. Commercial antibodies often vary in performance across applications, necessitating optimization. As chromatin remodeling gains attention in therapeutic development, SMARCA2 antibodies remain vital tools for exploring epigenetic mechanisms and identifying biomarkers or targets in disease contexts.
×
